Stock Market Reviews

CVAC (CureVac N.V.) News

Get the latest news, insights, and market updates on CVAC (CureVac N.V.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• CureVac (NasdaqGM:CVAC) Valuation After New mRNA Pipeline Progress And Refined Capital Allocation Plan
  Investor attention around CureVac (NasdaqGM:CVAC) has picked up after management outlined incremental progress in its second generation mRNA vaccine programs with GSK, along with a more focused capital allocation approach in oncology and prophylactic vaccines. See our latest analysis for CureVac. Those updates come after a volatile stretch for the shares. The 1 day share price return was a 14.32% decline and the 7 day share price return was a 19.18% decline. By contrast, the 1 year total...
  Jan 20, 2026 - $CVAC
• BioNTech SE (BNTX) Closes the Acquisition of CureVac N.V.
  BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC), which is another mRNA-focused biotech firm from Mainz, Germany. Management noted that the deal had closed after the expiration of the subsequent offering […]
  Dec 23, 2025 - $CVAC
• BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
  BioNTech has completed its exchange offer to acquire CureVacAcquisition complements BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturingIn total, approximately 86.75% of CureVac shares were tendered; BioNTech expects to complete the compulsory acquisition of the remaining CureVac shares in January 2026 as part of the previously announced post-offer reorganizationCureVac will continue to operate under its existing organizational proces
  Dec 18, 2025 - $CVAC
• CureVac Valuation After 2025 Rebound and DCF Suggests Large Gap to Fair Value
  Many investors are asking whether CureVac at $5.12 is a bargain or a value trap, and this is exactly the kind of stock where valuation really matters. The share price has pulled back over the last week and month, down 6.7% over 7 days and 2.8% over 30 days, but it is still up 48.4% year to date and 65.2% over the past year despite steep longer term losses. The recent rebound comes as investors refocus on CureVac's mRNA pipeline and strategic partnerships, which keep the story in focus even...
  Dec 6, 2025 - $CVAC
• CureVac N.V. (CVAC): A Bull Case Theory
  We came across a bullish thesis on CureVac N.V. on Ridire Research’s Substack. In this article, we will summarize the bulls’ thesis on CVAC. CureVac N.V.’s share was trading at $5.20 as of December 1st. CVAC’s trailing and forward P/E were 8.30 and 5.24 respectively according to Yahoo Finance. CureVac (CVAC) represents the most credible non-U.S. mRNA platform […]
  Dec 4, 2025 - $CVAC
• BioNTech Achieves Minimum Condition in CureVac Exchange Offer
  The minimum condition for the offer has been satisfied, with 184,071,410 shares of CureVac, representing approximately 81.74% of CureVac’s issued and outstanding shares, tendered prior to the expiration of the initial offering periodThe subsequent offering period has commenced and will expire at 12:01 a.m. Eastern Time on Thursday, December 18, 2025 MAINZ, Germany, December 3, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that 184,071,410 shares of CureVac N.V. (Nasdaq: CVAC, “Cu
  Dec 3, 2025 - $CVAC
• CureVac Announces Voting Results of Extraordinary General Meeting
  TÜBINGEN, DE AND BOSTON, MA / ACCESS Newswire / November 25, 2025 / CureVac N.V. (Nasdaq:CVAC)(CureVac or the Company), a pioneering multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA), today ...
  Nov 26, 2025 - $CVAC
• BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
  Offer set to expire at 9:00 am Eastern Time on December 3, 2025, with CureVac shareholders advised to tender their shares by 6:00 pm Eastern Time on December 2, 2025, due to operational deadlines.Exchange ratio of 0.05363 of a BioNTech American Depositary Share (“ADS”) for each CureVac share, determined based on the volume-weighted average price of BioNTech ADSs over the 10 trading days ending November 25, 2025.CureVac shareholders approved matters related to BioNTech’s exchange offer at their e
  Nov 26, 2025 - $CVAC
• How Investors May Respond To CureVac (CVAC) Reporting Sharp Decline in Quarterly Sales
  CureVac N.V. recently reported its third quarter and nine-month earnings, revealing sales of €54.13 million and net income of €273.23 million for the quarter, both down substantially from the previous year. This financial update highlights a very large year-over-year reduction in sales, signaling challenges for the company’s current revenue momentum. We'll explore how the pronounced decline in quarterly sales impacts CureVac's investment narrative and future business outlook. Explore 26 top...
  Nov 25, 2025 - $CVAC
• High Growth Tech Stocks In The US Market November 2025
  The United States market has recently seen a mix of gains and declines, with the Dow Jones Industrial Average and S&P 500 experiencing modest rises while the Nasdaq faced slight downward pressure amid fluctuating tech stock performances. In this dynamic environment, identifying high growth tech stocks requires careful consideration of factors such as innovation potential, market demand for technology solutions, and adaptability to changing economic conditions.
  Nov 25, 2025 - $CVAC